Baird analyst Eric Coldwell raised the firm’s price target on McKesson to $450 from $445 and keeps an Outperform rating on the shares. The analyst said US Pharma looks very healthy, Med-Surg is strong ex-COVID comps, International while less impactful and muddied by divestitures and FX is doing better than we expected, while Prescription Tech again stole some thunder.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on MCK:
